BMO Capital analyst Kostas Biliouris raised the firm’s price target on Alnylam (ALNY) to $360 from $300 and keeps an Outperform rating on the shares. Following Amvuttra approval in ATTR-CM on March 20, the firm has been highlighting weekly the significant uptick in Amvuttra sales reported by IQVIA (IQV), the analyst tells investors in a research note. Some investors are skeptical about the accuracy of IQVIA data, but BMO expects the accuracy of Q2 IQVIA sales to be similar to the past 5 quarters of ATTR-PN sale, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma Appoints New Chief R&D Officer
- Alnylam names Pushkal Garg as EVP, chief research and development officer
- Alnylam price target raised to $338 from $330 at JPMorgan
- Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections
- Alnylam receives European Commission approval of AMVUTTRA